Skip to main content
Premium Trial:

Request an Annual Quote

Roche Cobas HIV-1, HCV, and HCV Genotyping

Roche will make its Cobas HIV-1, hepatitis C virus, and HCV genotyping assays commercially available in countries accepting the CE mark, the firm announced today. The three assays can run simultaneously on the Cobas 4800 PCR system, which performs automated nucleic acid purification, PCR set-up, real-time amplification, and detection. The assays were CE-marked in December of last year, and add to a menu on the Cobas 4800 that also includes nine other in vitro diagnostic tests for infectious diseases and cancer-related mutations.

The dual-target HIV-1 assay amplifies two regions of the genome that are not subject to selective drug pressure, enabling more effective quantification of HIV-1 RNA in patient samples. The HCV detection assay is a dual-probe test to confirm active infection or assess response to antiviral therapy, while the HCV genotyping test identifies genotypes 1 to 6 as well as genotype 1 subtypes a and b in plasma or serum from chronically infected patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.